SUPN
Supernus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$44.09
+0.27%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
15.3x
EV/EBITDA
−140.6x
Market Cap
$2.56B
MomentumView details →
1D Return
+0.27%
YTD Return
−11.59%
RSI (14)
39.7
ValuationView details →
P/E (Fwd)
15.3x
EV/EBITDA
−140.6x
Market Cap
$2.56B
RSI (14)
39.7
MomentumView details →
1D Return
+0.27%
YTD Return
−11.59%
SummaryUpdated Jun 1, 2026
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a biopharmaceutical company founded in 2005 and headquartered in Rockville, Maryland. The company went public in 2012 and specializes in developing and commercializing treatments for central nervous system (CNS) disorders. Supernus has evolved from a company dependent on legacy epilepsy medications to one focused on growth products, particularly in ADHD and Parkinson's disease treatments. The company operates primarily in the United States market and has built a portfolio of both commercial products and pipeline candidates targeting various neurological and psychiatric conditions.
Similar companies
Latest newsMore news →
Supernus Pharmaceuticals announced a compensated ambassador partnership with professional snowboarder Chloe Kim to discuss her ADHD journey and treatment with Qelbree.4d agoAssenagon Asset Management S.A. reduced its stake in Supernus Pharmaceuticals, Inc. by 86.2% during the quarter, selling 457,443 shares and retaining 73,175 shares, as disclosed in a 13F filing.23d ago